A Multicenter, Randomized, Open Label, Cyclosporine Controlled Phase II Clinical Study Evaluating the Efficacy and Safety of Zuberitamab Injection (HS006) in Patients With Primary Membranous Nephropathy.

The article discusses a multicenter, randomized, open-label, cyclosporine-controlled Phase II clinical trial evaluating the efficacy and safety of Zuberitamab injection in patients with primary membranous nephropathy. The study aims to explore the Phase III dosing regimen, sample size, and endpoint evaluation time. The trial is not yet recruiting participants, with an enrollment target of 135 individuals aged 18 to 75 years, and is set to be completed by December 31, 2027. The study includes detailed eligibility criteria and contact information for the primary investigator in China. [Extracted from the article]